Umbellulone |cas 546-78-1| DC Chemicals

Cas No.:	546-78-1
Chemical Name:	(+-)-umbellulone
Synonyms:	(-)-Umbellulon;(-)-Umbellulone;(1R)-Thuj-3-en-2-on;(1R)-thuj-3-en-2-one;4-methyl-1-(1-methylethyl)-bicyclo[3.1.0]hex-3-en-2-one;Thuj-3-en-2-on;thuj-3-en-2-one;Umbellulon;Umbellulone;(1R, 5S)-4-Methyl-1-propan-2-ylbicyclo(3.1.0)hex-3-en-2-one;(1R,5S)-(-)-3-Thujen-2-one;Thujen-2-one;Thujenone;[1R,5S,(-)]-4-Methyl-1-isopropylbicyclo[3.1.0]hexa-3-ene-2-one;(+-)-umbellulone
SMILES:	CC([C@]12C[C@H]1C(=CC2=O)C)C
Formula:	C₁₀H₁₄O
M.Wt:	150.217563152313
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Umbellulone is an active constituent of the leaves of Umbellularia californica. Umbellulone stimulates the TRPA1 channel in a subset of peptidergic, nociceptive neurons, activating the trigeminovascular system via this mechanism[1].
Target:	TRPA1 channel[1]
In Vivo:	Umbellulone (50–250 nM/5ul) causes an acute nocioceptive response in a dose-dependent manner in Trpa1+/+ mice[1]. Umbellulone (150 µg/kg; intravenous or intranasal) do not affect systemic blood pressure[1]. Umbellulone (30-150 μg/kg; i.v.) increases meningeal blood flow in a dose-dependent manner[1]. Animal Model: Sprague-Dawley rats (male, 250 g)[1] Dosage: 30 μg/kg, 75 μg/kg, 150 μg/kg Administration: Intravenously Result: Increased meningeal blood flow in a dose-dependent manner.
In Vitro:	Umbellulone, from µM to sub-mM concentrations, selectively stimulates transient receptor potential ankyrin 1-expressing HEK293 cells[1].
References:	[1]. Nassini R, et al. The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain. 2012 Feb;135(Pt 2):376-90.

Cat. No.	Product name	Field of application
DC80295	Ponometrep(BBO-11818)	BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab, anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer.
DC76817	HZS60	HZS60 is a NMDAR/TRPM4 inhibitor with brain permeability that can improve cerebral ischemia. HZS60 has significant neuroprotective effects on primary neuronal ischemic damage caused by NMDA and oxygen-glucose deprivation/reoxygenation. HZS60 exhibits good pharmacokinetic characteristics and can inhibit cerebral ischemia-reperfusion injury. HZS60 can be used as a potential inhibitor of ischemic stroke.
DC73692	GNE551	GNE551 is a potent, selective, non-covalent agonist of TRPA1 ion channel with EC50 of 254 nM in Ca2+ influx assays.
DC70937	ZINC17988990	ZINC 17988990 is a potent, selective inhibitor of TRPV5 mediated currents, inhibits rbTRPV5/hTRPV5 with IC50 of 106/177 nM, showing marked selectivity for TRPV5 over TRPV6.ZINC 17988990 shows no activity on other TRP channels (TRPV1, TRPV3, TRPV4 and TRPM8) at 1-3 uM, and moderate inhibition on TRPV3 and TRPM8 at >10 uM.ZINC17988990 (10 uM) fully inhibited Ca2+ signals elicited by application of external Ca2+ in HEK293 cells transfected with TRPV5, but had no effect in cells expressing TRPV6.
DC70523	JNJ-28583113	JNJ-28583113 (JNJ28583113) a potent, selective, brain penetrant TRPM2 antagonist with IC50 of 126 nM (hTRPM2).JNJ-28583113 shows similar potency against species chimpanzee and rat TRPM2 with IC50 of 100 and 25 nM, respectively.JNJ-28583113 shows no significant (IC50>10 uM) reactivity towards PARP or PARG and a panel for multiple known kinases GPCRs and ion channels, nine other TRP channels with exception of TRPM5 (IC50<1 uM).Blocking TRPM2 via JNJ-28583113 caused phosphorylation of GSK3α and β subunits in cell assays.JNJ-28583113 also protected cells from oxidative stress induced cell death as well as morphological changes induced by non-cytotoxic concentrations of H2O2。JNJ-28583113 blunted cytokine release in response to pro-inflammatory stimuli in microglia.JNJ-28583113 was brain penetrant but not suitable for systemic dosing as it was rapidly metabolized in vivo, but the in-vitro pharmacology of JNJ-28583113 is the best in class.
DC70430	GDC-0334	GDC-0334 (GDC0334) is a highly potent, selective, orally bioavailable TRPA1 antagonist with IC50 of 1.7 nM in cell-based assays.GDC-0334 demonstrated potent TRPA1 inhibition in several species, including human (IC50=1.7 nM), cynomolgus (IC50=3.6 nM), mouse (IC50=2.7 nM), guinea pig (IC50=11.1 nM), and dog (IC50=102 nM).GDC-0334 displays good selectivity against human TRPV1, TRPM8, and TRPC6 (all IC50s>10 uM).GDC-0334 also inhibits calcium flux in human primary cells, HASMCs and HLFs, treated with the TRPA1 agonist AITC.GDC-0334 suppresses AITC-induced edema in vivo in rat (1-10 mg/kg), reduces OVA-induced asthma model in rats and guinea pigs and guinea pig model of cough.GDC-0334 is a potent inhibitor of AITC-induced dermal blood flow (DBF) in vivo in rats and guinea pigs, reduces AITC-induced perfusion and nocifensive behavior in rats and itch and pain scores in humans.
DC47315	ML-SI3	ML-SI3 is a potent TRPML channel inhibitor with IC50s of 4.7 µM and 1.7 µM for TRPML1 and TRPML2, respectively.
DC46872	Evifacotrep	Evifacotrep, a short transient receptor potential channel 5 (TRPC5) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases.
DC46871	Vocacapsaicin	Vocacapsaicin (CA-008), a prodrug of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin can provide meaningful and long-lasting pain relief.
DC46699	9-Phenanthrol	9-Phenanthrol (9-Hydroxyphenanthrene, Phenanthren-9-o, 9-Phenanthrenol) is a selective TRPM4 inhibitor with an IC50 in the range of 0.02 μM, without effects on TRPM5.